menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Exploring Early Usage of a 2L ITP Treatment Option: Clinical Profile and Access Resources

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Explore the clinical and safety profile of a 2L therapy option, including treatment-free remission data. Where could your ITP patients be in 6 months?

  • Sponsored by

  • Overview

    While there is no cure for immune thrombocytopenia (ITP), choosing a potential second-line treatment option for ITP patients right after insufficient response to steroids is key to maintaining platelet stability.1,2 Dr. Steven Fein, who’s the founder of Heme On Call, a telemedicine-based benign hematology practice, joins Dr. Charles Turck to dive deep into the safety and clinical profile of Nplate®, including treatment-free remission data and real-world evidence that supports it. 

    References:

    1. Newland A, Godeau B, Priego V, et al. Br J Haematol. 2016;172(suppl):1-4. doi:10.1111/bjh.13827.
    2. Rituxan® (rituximab) prescribing information, Genentech, Inc., 2021.

    ©2024 Amgen Inc. All rights reserved. USA-531-81218 2/24

  • INDICATION

    Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

    Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

  • IMPORTANT SAFETY INFORMATION

    Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

    • In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
    • Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than ITP.

    Thrombotic/Thromboembolic Complications

    • Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate® use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate®
    • To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of ≥ 50 x 109/L.

    Loss of Response to Nplate® 

    • Hyporesponsiveness or failure to maintain a platelet response with Nplate® should prompt a search for causative factors, including neutralizing antibodies to Nplate®.
    • To detect antibody formation, submit blood samples to Amgen (1-800-772-6436). Amgen will assay these samples for antibodies to Nplate® and thrombopoietin (TPO).
    • Discontinue Nplate® if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the highest weekly dose of 10 mcg/kg.

    Adverse Reactions

    • In the placebo-controlled trials, headache was the most commonly reported adverse drug reaction, occurring in 35% of patients receiving Nplate® and 32% of patients receiving placebo. Adverse drug reactions with ≥ 5% higher patient incidence in Nplate® versus placebo were Arthralgia (26%, 20%), Dizziness (17%, 0%), Insomnia (16%, 7%), Myalgia (14%, 2%), Pain in Extremity (13%, 5%), Abdominal Pain (11%, 0%), Shoulder Pain (8%, 0%), Dyspepsia (7%, 0%), and Paresthesia (6%, 0%).
    • The safety profile of Nplate® was similar across patients, regardless of ITP duration. The following adverse reactions (at least 5% incidence and at least 5% more frequent with Nplate® compared with placebo or standard of care) occurred in Nplate® patients with ITP duration up to 12 months: bronchitis, sinusitis, vomiting, arthralgia, myalgia, headache, dizziness, diarrhea, upper respiratory tract infection, cough, nausea and oropharyngeal pain. The adverse reaction of thrombocytosis occurred with an incidence of 2% in adults with ITP duration up to 12 months.

    Nplate® administration may increase the risk for development or progression of reticulin fiber formation within the bone marrow. This formation may improve upon discontinuation of Nplate®. In a clinical trial, one patient with ITP and hemolytic anemia developed marrow fibrosis with collagen during Nplate® therapy.

    Please see full Prescribing Information and Medication Guide

Schedule22 Jun 2024